共 50 条
- [21] Refining frailty in relapsed or refractory multiple myeloma: adding the patient voice [J]. LANCET HEALTHY LONGEVITY, 2022, 3 (09): : E579 - E580
- [24] Patient eligibility for lenalidomide/dexamethasone treatment in relapsed/refractory multiple myeloma [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 97 - 97